Evi-1 Antibody (2331C1a1): sc-130025

Evi-1 Antibody (2331C1a1) is a mouse monoclonal IgG1 antibody that recognizes Evi-1 in human samples through western blotting (WB) and immunoprecipitation (IP) applications. Evi-1, a proto-oncogene, plays a critical role in regulating gene expression and cellular differentiation, particularly in hematopoietic cells. Evi-1 (2331C1a1) antibody enables research into transcriptional regulation of various genes, including those that control cell proliferation and survival. Evi-1 contains two zinc finger domains, with the second domain being crucial for transactivating the c-Fos promoter and activating the AP-1 signaling pathway, which is essential for cellular responses to growth factors and stress. The first zinc finger domain interacts with Smad3, leading to the suppression of TGFβ signaling, a pathway that normally inhibits cell growth and promotes differentiation. Dysregulation of Evi-1 expression has been implicated in the pathogenesis of acute myelogenous leukemia (AML) and myelodysplastic syndromes, making anti-Evi-1 antibody (2331C1a1) a significant tool for research into hematological malignancies and exploring potential therapeutic interventions.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Evi-1 Antibody (2331C1a1) References:

1. Oncogenic mechanisms of Evi-1 protein.  |  Hirai, H., et al. 2001. Cancer Chemother Pharmacol. 48 Suppl 1: S35-40. PMID: 11587364
2. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP.  |  Nitta, E., et al. 2005. Oncogene. 24: 6165-73. PMID: 15897867
3. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells.  |  Goyama, S., et al. 2008. Cell Stem Cell. 3: 207-20. PMID: 18682242
4. The role of Runx1/AML1 and Evi-1 in the regulation of hematopoietic stem cells.  |  Kumano, K. and Kurokawa, M. 2010. J Cell Physiol. 222: 282-5. PMID: 19847803
5. Evi-1 as a critical regulator of leukemic cells.  |  Goyama, S. and Kurokawa, M. 2010. Int J Hematol. 91: 753-7. PMID: 20532840
6. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.  |  Arai, S., et al. 2011. Blood. 117: 6304-14. PMID: 21190993
7. Identification of Evi-1 as a novel effector of PKCδ in the apoptotic response to DNA damage.  |  Hew, HC., et al. 2011. Biochim Biophys Acta. 1809: 285-94. PMID: 21362509
8. Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.  |  Deng, X., et al. 2013. Mol Carcinog. 52: 255-264. PMID: 22161860
9. RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study.  |  Shen, L., et al. 2015. BMC Cancer. 15: 970. PMID: 26674644
10. Evi-1 Influence on Clinical Progress of Colorectal Cancer Patients.  |  Zhu, Y., et al. 2020. Ann Clin Lab Sci. 50: 354-360. PMID: 32581025

The preferred Evi-1 antibody is Evi-1 Antibody (H-8): sc-515456.